CNBC December 28, 2023
Key Points
– U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024.
– Next year could set the precedent for a controversial process that may affect the prices seniors pay for dozens of medications by the end of the decade.
– It could also be a pivotal year for the lawsuits that drugmakers – including Merck, Johnson & Johnson and Bristol Myers Squibb – have filed against the price talks.
U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the precedent for a controversial process that may affect what seniors pay for dozens of medications by...
Today's Sponsors
Today's Sponsor
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech